Tightening Hospice Regulation May Give Some Buyers Pause in M&A Deals

Posted November 30, 2022

The increasing regulatory attention in the hospice industry could impact buyers’ mergers and acquisitions decisions.

The details in the regulatory environment can be challenging to navigate, likely more so for private equity and venture capital investors that are new to the industry. Changes to federal enforcement practices during the next year could bring some additional pressure, according to Erin Burns, senior associate at health care law firm Husch Blackwell.

“Hospice transactions are more complicated than just your average business deal,” Burns said in a recent Husch Blackwell podcast. “On the corporate side of things, they can sometimes be 10 steps ahead and have not given thought to the regulatory considerations, which can put some time constraints on your deal and could impact timing of closing and other things.”

Click here for the full article.

About Corridor

For over 30 years, Corridor has partnered with home-based care providers, delivering powerful solutions to support the unique challenges of caring for patients in the home. Our team of operating executives, clinicians, and nationally renowned industry experts have run provider organizations and resolved the same challenges you face.

To receive the most important industry updates, insights and news impacting home health and hospice, please make sure to sign up for our weekly newsletter.

Explore Corridor’s Solutions

Share This Story, Choose Your Platform!